



Mr. MANOHAR LAL

PID NO: 46299 Age: 29 Years Sex: Male

DOB: 07-Jan-1996

Reference: Dr. AISHA UMER

**Referred Client:** 

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5070110200

Collected on:

Registered on: 30-Jul-2025 01:27 PM

Reported on:

## **Abnormal Result(s) Summary**

Abhorniai Nesuit(s) Summary							
Test Name	Result Value	Unit	Reference Range				
CHOLESTEROL (TOTAL)	231	mg/dL	Desirable: < 200 Borderline High: 200 - 239 High: = 240 Please note change. Source: Roche IFU.				
LDL CHOLESTEROL DIRECT	156	mg/dL	Optimal: < 100 Near/Above Optimal: 100 - 129 Borderline High: 130 - 159 High: 160 - 189 Very High: = or > 190 Please note change. Source: Roche IFU.				
TRIGLYCERIDES	250	mg/dL	Normal: < 150 Borderline High: 150 - 199 High: 200 - 499 Very High: > 500 Source: Roche IFU.				
VLDL CHOLESTEROL	50	mg/dL	< 30				
NON-HDL CHOLESTEROL	206	mg/dL	< 140				
LDL / HDL RATIO	3.8		< 3.5				
TOTAL CHOLESTEROL / HDL RATIO	5.6		< 4.5				

Test Remark: Note: Please correlate clinically.

Abnormal Result(s) Summary End

This is an Electronically Authenticated Report.

).

30-Jul-2025 04:00 PM

Printed on:







Mr. MANOHAR LAL

PID NO: 46299

Age: 29 Years Sex: Male DOB: 07-Jan-1996

Reference: Dr. AISHA UMER

**Referred Client:** 

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5070110200

Collected on:

29-Jul-2025 11:40 AM

Registered on:

30-Jul-2025 01:27 PM

Reported on:

30-Jul-2025 03:48 PM

<u>Investigation</u>	Observed Value Flag	<u>Unit</u>	Biological Reference In	terval <u>Method</u>
COMPLETE BLOOD COUNT (CBC)				
HEMOGLOBIN	14.5	g/dL	13.5 - 17.5	Photometric
RBC COUNT	4.6	5/ GE 10^6/μL	4.3 - 5.7	Electrical Impedance
HEMATOCRIT	42.1	%	38 - 50	Calculation
MCV	91.7	fL	82 - 98	Calculation
MCH	31.5	pg	27 - 32	Calculation
MCHC	34.4	g/dL	32 - 37	Calculation
* RDW	14.9	%	11.8 - 15.6	Calculation
* RDW-SD	47.30	fL	11.0 13.0	Calculation
MPV	10.7	fL	7.6 - 10.8	Calculation
PLATELET COUNT	227	10^3/uL	150 - 450	Electrical Impedance
* NUCLEATED RBC (NRBC)	0.30	/100 WBC	130 130	VCS 360 Technology
* ABSOLUTE NRBC COUNT	0.02	10^3/uL		Calculation
TOTAL & DIFFERENTIAL COUNT (DC)	0.02	20 0,02		
WBC COUNT	5.7	10^3/μL	4 - 11	Electrical Impedance
NEUTROPHILS	51	%	40 - 75	VCS 360 Technology
LYMPHOCYTES	41	%	20 - 45	VCS 360 Technology
EOSINOPHILS	4	%	0 - 6	VCS 360 Technology
MONOCYTES	4	%	1 - 6	VCS 360 Technology
BASOPHILS	0	%	0 - 1	VCS 360 Technology
ABSOLUTE COUNT				
ABSOLUTE NEUTROPHIL COUNT	2.91	10^3/uL	1.6 - 8.25	Calculation
ABSOLUTE LYMPHOCYTE COUNT	2.34	10^3/uL	0.8 - 4.95	Calculation
ABSOLUTE MONOCYTE COUNT	0.23	10^3/uL	0.04 - 0.66	Calculation
ABSOLUTE EOSINOPHIL COUNT	0.23	10^3/uL	0 - 0.66	Calculation
ABSOLUTE BASOPHIL COUNT	0	10^3/uL	0 - 0.11	Calculation

Sample Type: EDTA Whole Blood

ayana V. Shah

**DR. ADLEY MARK FERNANDES** M.D (Pathology)

**Pathologist** 

DR. VYOMA SHAH M.D (Pathology) **Clinical Pathologist** 

This is an Electronically Authenticated Report.

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (\*). Test marked with # is performed in an accredited referral laboratory.








**ANJUMOL VADAKKINATHU** 

Laboratory Technologist







PID NO: 46299

Age: 29 Years Sex: Male DOB: 07-Jan-1996

Reference: Dr. AISHA UMER

**Referred Client:** 

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5070110200

Collected on:

29-Jul-2025 11:40 AM

Registered on:

30-Jul-2025 01:27 PM

Reported on:

30-Jul-2025 03:07 PM

**Investigation Observed Value Flag** Unit **Biological Reference Interval** 

< 0.6

\* C-REACTIVE PROTEIN (CRP)

(Serum, Particle-enhanced immunoturbidimetric assay)

< 5.0 mg/L

> Please note change. Source: Roche IFU.

INTERPRETATION:

- CRP measurements are used as aid in diagnosis, monitoring, prognosis, and management of suspected inflammatory disorders and associated diseases, acute infections and tissue injury.
- C-reactive protein is the classic acute phase protein in inflammatory reactions.
- CRP is the most sensitive of the acute phase reactants and its concentration increases rapidly during inflammatory processes. The CRP response frequently precedes clinical symptoms, including fever. After onset of an acute phase response, the serum CRP concentration rises rapidly and extensively. The increase begins within 6 to 12 hours and the peak value is reached within 24 to 48 hours. Levels above 100 mg/L are associated with severe stimuli such as major trauma and severe infection (sepsis).
- CRP response may be less pronounced in patients suffering from liver disease.
- CRP assays are used to detect systemic inflammatory processes (apart from certain types of inflammation such as systemic lupus erythematosus (SLE) and Colitis ulcerosa); to assess treatment of bacterial infections with antibiotics; to detect intrauterine infections with concomitant premature amniorrhexis; to differentiate between active and inactive forms of disease with concurrent infection, e.g. in patients suffering from SLE or Colitis ulcerosa; to therapeutically monitor rheumatic disease and assess anti-inflammatory therapy; to determine the presence of post-operative complications at an early stage, such as infected wounds, thrombosis and pneumonia, and to distinguish between infection and bone marrow transplant rejection."

ayona V. Shah

DR. VYOMA SHAH M.D (Pathology) **Clinical Pathologist** 

This is an Electronically Authenticated Report.

**DR. ADLEY MARK FERNANDES** 

M.D (Pathology)

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (\*). Test marked with # is performed in an accredited referral laboratory.









**BHAVYA THENDANKANDY** 

Laboratory Technician





Mr. MANOHAR LAL

PID NO: 46299 Age: 29 Years Sex: Male

DOB: 07-Jan-1996

Reference: Dr. AISHA UMER

**Referred Client:** 

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5070110200

Collected on:

29-Jul-2025 11:40 AM

Registered on:

30-Jul-2025 01:27 PM Reported on:

30-Jul-2025 03:58 PM

Investigation	Observed Value	<u>Flag</u>	<u>Unit</u>	<b>Biological Reference Interval</b>			
LIPID PROFILE							
CHOLESTEROL (TOTAL) (Serum, UV Enzymatic)	231	Н	mg/dL	Desirable: < 200 Borderline High: 200 - 239 High: = 240 Please note change. Source: Roche IFU.			
HDL CHOLESTEROL	41		mg/dL	40 - 60			
(Serum, Homogeneous Microparticle Agglutination)							
LDL CHOLESTEROL DIRECT (Serum, Homogeneous Microparticle Agglutination)	156	Н	mg/dL	Optimal: < 100 Near/Above Optimal: 100 - 129 Borderline High: 130 - 159 High: 160 - 189 Very High: = or > 190 Please note change. Source: Roche IFU.			
TRIGLYCERIDES (Serum, UV Enzymatic)	250	Н	mg/dL	Normal: < 150 Borderline High: 150 - 199 High: 200 - 499 Very High: > 500 Source: Roche IFU.			
VLDL CHOLESTEROL (Serum, Calculation)	50	Н	mg/dL	< 30			
NON-HDL CHOLESTEROL (Serum, Calculation)	206	Н	mg/dL	< 140			
LDL / HDL RATIO (Serum, Calculation)	3.8	Н		< 3.5			
TOTAL CHOLESTEROL / HDL RATIO (Serum, Calculation) Note: Please correlate clinically.	5.6	Н		< 4.5			
End Of Report							

**DR. ADLEY MARK FERNANDES** 

M.D (Pathology) M.D (Pathology) **Pathologist Clinical Pathologist** 

This is an Electronically Authenticated Report.

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (\*). Test marked with # is performed in an accredited referral laboratory.

Oyana V. Shah

DR. VYOMA SHAH



**BHAVYA THENDANKANDY** 

Laboratory Technician

30-Jul-2025 04:00 PM



